Selcaxen 40 mg (Selpercatinib) Capsules

Selcaxen 40 mg Capsules contain selpercatinib, a targeted anticancer medicine designed to inhibit abnormal RET gene alterations that drive the growth and spread of certain cancers. It is primarily used in adults with RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC), and RET fusion-positive thyroid cancers requiring systemic treatment. By specifically targeting RET signaling pathways, this therapy may help slow tumor progression, reduce cancer cell growth, and improve disease control while limiting damage to healthy cells compared with conventional chemotherapy. Treatment should be initiated and monitored by an experienced oncology specialist.

Each capsule contains Selpercatinib 40 mg as the active pharmaceutical ingredient. Selpercatinib belongs to the class of targeted anticancer medicines known as RET kinase inhibitors. The formulation may also contain pharmaceutical-grade inactive ingredients that support capsule stability, absorption, and product integrity. The medicine is developed to provide precise inhibition of RET-driven cancer pathways and is intended for use under professional medical supervision.

The recommended dosage should be determined by the treating physician based on body weight, medical condition, treatment response, and overall clinical assessment. Capsules should be swallowed whole with water and may be taken with or without food unless otherwise directed by a healthcare professional. The medicine should be taken at the same time each day to maintain consistent therapeutic levels. If a dose is missed, follow the advice of the prescribing physician or product prescribing information. Patients should not alter, crush, chew, or discontinue treatment without consulting their healthcare provider. Regular monitoring of liver function, blood pressure, and treatment response may be required during therapy to ensure optimal safety and effectiveness.